You are here Home Vaccines Vaccines Pneumovax 23 Details for Pneumovax 23 (23vPPV) vaccine and its components. Listen Print Share Twitter Facebook Email Recently added This page was added on 04 June 2018. Updates made This page was updated on [date-counter-updated-date]. View history of updates Sponsor Merck Sharp & Dohme (Australia) Administration route Intramuscular injection Subcutaneous injection Vaccine group Pneumococcal polysaccharide vaccine Description: Registered for use in children aged ≥2 years and in adults. 23vPPV — 23-valent pneumococcal polysaccharide vaccine Each 0.5 mL monodose vial contains: 25 µg each of pneumococcal capsular polysaccharide of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F 0.25% phenol For Product Information and Consumer Medicine Information about Pneumovax 23 visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s. Related diseases Pneumococcal disease Page history Last updated 4 June 2018 Last reviewed 4 June 2018 Is there anything wrong with this page? Help us improve the Australian Immunisation Handbook What you were doing? (required) What went wrong? (required) Leave this field blank
